Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$0.94
-0.5%
$0.94
$0.03
$1.03
$5.59M0.542,709 shs2,402 shs
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
$4.57
+2.2%
$3.76
$0.64
$5.14
$20.39M0.46117,229 shs94,396 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.60
-5.5%
$3.62
$2.57
$6.88
$23.54M0.574,224 shs5,033 shs
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
$2.85
-1.7%
$4.05
$1.08
$19.30
$19.80M1.21546,325 shs347,480 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00%0.00%0.00%0.00%+16.88%
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
+2.24%+2.70%+2.01%+243.66%+138.02%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-5.51%-7.10%-1.64%+5.73%-46.51%
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
-1.72%-12.31%-4.36%+128.00%-60.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$0.94
-0.5%
$0.94
$0.03
$1.03
$5.59M0.542,709 shs2,402 shs
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
$4.57
+2.2%
$3.76
$0.64
$5.14
$20.39M0.46117,229 shs94,396 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.60
-5.5%
$3.62
$2.57
$6.88
$23.54M0.574,224 shs5,033 shs
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
$2.85
-1.7%
$4.05
$1.08
$19.30
$19.80M1.21546,325 shs347,480 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00%0.00%0.00%0.00%+16.88%
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
+2.24%+2.70%+2.01%+243.66%+138.02%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-5.51%-7.10%-1.64%+5.73%-46.51%
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
-1.72%-12.31%-4.36%+128.00%-60.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00
N/AN/AN/A
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
3.00
Buy$20.00601.75% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$10.06M0.56N/AN/A$1.66 per share0.56
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/AN/AN/AN/A($1.19) per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$125.48M0.18N/AN/A$13.32 per share0.27
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
$20K973.28N/AN/A($0.71) per share-4.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
-$5.69M-$1.41N/AN/AN/AN/AN/AN/A
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
-$3.59M-$1.29N/AN/AN/AN/A-222.90%11/10/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
-$7.44MN/A0.00N/AN/A-4,646.10%-342.21%N/A

Latest FRTX, NAII, LIXT, and SONN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q3 2025
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
-$0.49-$0.95-$0.46-$0.95N/AN/A
8/7/2025Q2 2025
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/A-$0.29N/A-$0.29N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/AN/AN/A
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/A
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/A
1.84
1.84
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
N/A
0.26
0.26
CompanyEmployeesShares OutstandingFree FloatOptionable
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
205.97 million5.96 millionNot Optionable
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
44.56 million3.89 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
106.83 million6.25 millionNot Optionable

Recent News About These Companies

Sonnet Releases Virtual Investor "What This Means" Segment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fresh Tracks Therapeutics stock logo

Fresh Tracks Therapeutics NASDAQ:FRTX

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Lixte Biotechnology stock logo

Lixte Biotechnology NASDAQ:LIXT

$4.57 +0.10 (+2.24%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$4.57 0.00 (-0.11%)
As of 09/5/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.60 -0.21 (-5.51%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$3.57 -0.03 (-0.81%)
As of 09/5/2025 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Sonnet BioTherapeutics stock logo

Sonnet BioTherapeutics NASDAQ:SONN

$2.85 -0.05 (-1.72%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.90 +0.04 (+1.58%)
As of 09/5/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.